This suggests that the expression profile alterations across three cohorts might entail a few similar biological outcomes, but differences between STAD patient groups do not involve phenomena unique to the “midnightblue” module specific to ACC and DLBC, e.g., metabolic reprogramming or TP53 regulatory network. The gene discussed is TP53; the disease is adrenal cortex carcinoma.